Mostra el registre d'ítem simple

dc.contributor.authorBonjoch Badia, Anna
dc.contributor.authorPuig, Jordi
dc.contributor.authorPérez Álvarez, Nuria
dc.contributor.authorJuega Mariño, Javier
dc.contributor.authorEcheverria Liras, Patricia
dc.contributor.authorClotet Sala, Bonaventura
dc.contributor.authorRomero, Ramon
dc.contributor.authorBonet, Josep
dc.contributor.authorNegredo Puigmal, Eugènia
dc.contributor.otherUniversitat Politècnica de Catalunya. Departament d'Estadística i Investigació Operativa
dc.date.accessioned2017-06-12T14:35:08Z
dc.date.available2017-06-12T14:35:08Z
dc.date.issued2016-08
dc.identifier.citationBonjoch, A., Puig, J., Perez, N., Juega, J., Echeverria, P., Clotet, B., Romero, R., Bonet, J., Negredo, E. Impact of protease inhibitors on the evolution of urinary markers: subanalyses from an observational cross-sectional study. "Medicine", Agost 2016, vol. 95, núm. 32, p. 1-5.
dc.identifier.issn0025-7974
dc.identifier.urihttp://hdl.handle.net/2117/105361
dc.description.abstractKidney injury (defined as the presence of albuminuria, proteinuria, glycosuria [without hyperglycemia], hematuria, and/or renal hypophosphatemia) is an emerging problem in human immunodeficiency virus (HIV)-infected patients, although few data are available on the role of protease inhibitors (PIs) in this condition. To determine the time to kidney injury in a cohort of HIV-infected patients receiving a PI-containing regimen. We report the results of a subanalysis of a published cross-sectional study. The subanalysis included only patients receiving PI-containing regimens for more than 6 months (377 of the overall 970 patients). We determined associated factors and constructed receiver operating characteristic curves to estimate time to kidney injury depending on the PI used. The percentage of patients with kidney injury was 27.7% for darunavir, 27.9% for lopinavir, and 30% for atazanavir. Time to kidney injury was as follows: 229 days for atazanavir/ritonavir (area under the curve [AUC], 0.639; sensitivity, 0.89; specificity, 0.41); 332 days for atazanavir/ritonavir plus tenofovir (AUC, 0.603; sensitivity, 0.75; and specificity, 0.29); 318 days for nonboosted atazanavir (AUC, 0.581; sensitivity, 0.89; and specificity, 0.29); 478 days for lopinavir/ritonavir (AUC, 0.566; sensitivity, 0.864; and specificity, 0.44); 1339 days for lopinavir/ritonavir plus tenofovir (AUC, 0.667; sensitivity, 0.86; and specificity, 0.77); 283 days for darunavir/ritonavir (AUC, 0.523; sensitivity, 0.80; and specificity, 0.261); and 286 days for darunavir/ritonavir plus tenofovir (AUC, 0.446; sensitivity, 0.789; and specificity, 0.245). The use of lopinavir/ritonavir without tenofovir was a protective factor (odds ratio = 1.772; 95% CI, 1.070-2.93; P = 0.026). For all PIs, the percentage of patients with kidney injury exceeded 27%, irrespective of tenofovir use. The longest time to kidney injury was recorded with lopinavir/ritonavir. These results demonstrate the need for renal monitoring, including urine samples, in patients receiving a PI-based regimen, even when tenofovir is not used concomitantly.
dc.format.extent5 p.
dc.language.isoeng
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 Spain
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
dc.subjectÀrees temàtiques de la UPC::Matemàtiques i estadística::Investigació operativa
dc.subject.otherAIDS
dc.subject.otherHIV
dc.subject.otherkidney impairment
dc.subject.othernephrotoxicity
dc.subject.otherprotease inhibitors
dc.subject.otherproteinuria
dc.titleImpact of protease inhibitors on the evolution of urinary markers: subanalyses from an observational cross-sectional study
dc.typeArticle
dc.contributor.groupUniversitat Politècnica de Catalunya. GRBIO - Grup de Recerca en Bioestadística i Bioinformàtica
dc.identifier.doi10.1097/MD.0000000000004507
dc.description.peerreviewedPeer Reviewed
dc.subject.amsClassificació AMS::92 Biology and other natural sciences::92C Physiological, cellular and medical topics
dc.relation.publisherversionhttp://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2016&issue=08090&article=00034&type=abstract
dc.rights.accessOpen Access
local.identifier.drac19841858
dc.description.versionPostprint (published version)
local.citation.authorBonjoch, A.; Puig, J.; Perez, N.; Juega, J.; Echeverria, P.; Clotet, B.; Romero, R.; Bonet, J.; Negredo, E.
local.citation.publicationNameMedicine
local.citation.volume95
local.citation.number32
local.citation.startingPage1
local.citation.endingPage5


Fitxers d'aquest items

Thumbnail

Aquest ítem apareix a les col·leccions següents

Mostra el registre d'ítem simple